CardioSource WorldNews Interventions October 2014 | Page 3

January 22-24, 2015

January 30-February 1, 2015

Hilton Orlando Bonnet Creek/
Waldorf Astoria
Orlando, FL

Mountain Lodge Conference Center
Snowshoe, WV

Cardiovascular Summit:
Solutions for Thriving in a
Time of Change

January 30-February 1, 2015

May 7-9, 2015

sponsored by: University of Florida

34th Annual Cardiovascular
Conference at Snowshoe (ACC
Co-sponsored)

Heart House
Washington, DC

34th Annual Perspectives
on New Diagnostic and
Therapeutic Techniques in
Clinical Cardiology
(ACC Co-sponsored)
College of Medicine

Lake Buena Vista, FL

Effient® (prasugrel) is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients
with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI) as follows: [1] patients with
unstable angina (UA) or non–ST-elevation myocardial infarction (NSTEMI); [2] patients with ST-elevation myocardial infarction (STEMI)
when managed with primary or delayed PCI.
The loading dose (LD) of Effient is 60 mg and the maintenance dose (MD) is 10 mg once daily. Effient is available in 5-mg and 10-mg tablets.

IMPORTANT SAFETY INFORMATION
WARNING: BLEEDING RISK
Effient® (prasugrel) can cause significant, sometimes
fatal, bleeding.
Do not use Effient in patients with active pathological
bleeding or a history of transient ischemic attack or stroke.
In patients ≥75 years of age, Effient is generally not
recommended, because of the increased risk of fatal and
intracranial bleeding and uncertain benefit, except in
high-risk situations (patients with diabetes or a history of
prior myocardial infarction [MI]) where its effect appears
to be greater and its use may be considered.
Do not start Effient in patients likely to undergo urgent
coronary artery bypass graft surgery (CABG). When possible,
discontinue Effient at least 7 days prior to any surgery.
Additional risk factors for bleeding include:
body weight <60 kg
propensity to bleed
concomitant use of medications that increase the
risk of bleeding (eg, warfarin, heparin, fibrinolytic
therapy, chronic use of nonsteroidal anti-inflammatory
drugs [NSAIDs])
Suspect bleeding in any patient who is hypotensive and has
recently undergone coronary angiography, percutaneous
coronary intervention (PCI), CABG, or other surgical
procedures in the setting of Effient.
If possible, manage bleeding without discontinuing Effient.
Discontinuing Effient, particularly in the first few weeks
after acute coronary syndrome, increases the risk of
subsequent cardiovascular events.

CONTRAINDICATIONS
Effient is contraindicated in patients with active
pathological bleeding, such as from a peptic ulcer or
intracranial hemorrhage (ICH), or a history of transient
ischemic attack (TIA) or stroke, and in patients with
hypersensitivity to prasugrel or any component
of the product

WARNINGS AND PRECAUTIONS
Patients who experience a stroke or TIA while on Effient
generally should have therapy discontinued. Effient
should also be discontinued for active bleeding and
elective surgery
Premature discontinuation of Effient increases risk
of stent thrombosis, MI, and death
Thrombotic thrombocytopenic purpura (TTP), a
rare but serious condition that can be fatal, has been
reported with Effient, sometimes after a brief exposure
(<2 weeks), and requires urgent treatment, including
plasmapheresis
Hypersensitivity, including angioedema, has been
reported in patients receiving Effient, including patients
with a history of hypersensitivity reaction to other
thienopyridines

ADVERSE REACTIONS
Bleeding, including life-threatening and fatal bleeding,
is the most commonly reported adverse reaction
Please see Brief Summary of Prescribing Information,
including Boxed Warning regarding bleeding risk, on
subsequent pages.

®
Effient and Effient logo are registered trademarks of Eli Lilly and Company.
© 2014 Daiichi Sankyo, Inc. and Lilly USA, LLC. All Rights Reserved.
PG91514. PGHCPISI03Oct2011. Printed in USA. August 2014

37th Annual Recent Advances
in Clinical Nuclear Cardiology
and Cardiac CT: Mхє